The Physicians Really Are Healing Themselves, With Ozempic
1 day ago · Then he started taking Ozempic, the Novo Nordisk diabetes drug that is sold under the name Wegovy for obesity. He later switched to Mounjaro, from Eli Lilly, which is sold as Zepbound for obesity.
Novo Nordisk defends next-gen obesity drug CagriSema, details …
6 days ago · In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight …
Dec 20, 2024 · Novo Nordisk said Friday that in the study of just over 3,400 patients, its new injectable weight loss drug CagriSema met its primary goal, with an average weight loss of 22.7% of a patient's...
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss …
Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy.
What is CagriSema? The next-gen Ozempic weight loss drug
Nov 18, 2024 · Novo Nordisk (NVO-0.96%) — the company credited with ushering in the current weight-loss drug revolution when it launched its blockbuster diabetes treatment Ozempic in 2017 — is working on its...
What the results of Wegovy’s longest clinical trial yet show about ...
May 13, 2024 · More than 25,000 people in the US are starting Wegovy every week, drugmaker Novo Nordisk said this month. And in a KFF poll released Friday, 6% of respondents said they were currently using a...
Weight loss: Amycretin pill may be more effective than semaglutide
Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have developed to treat obesity —...
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Jan 17, 2025 · Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival...